Gökosmanoğlu, FeyziÖnmez, AttilaTopkaya, Sibel2020-04-302020-04-3020192667-663Xhttps://doi.org/10.4328/ACAM.5983https://hdl.handle.net/20.500.12684/5000WOS: 000512905300002Aim: In Type 2 diabetic patients, the prevalence of liver disease is high when compared with the general population. For this reason, the hepatic safety of anti-diabetes agent is important. However, there are uncertainties about the long-term efficiency and reliability of vildagliptin treatment. In this study, we have reviewed the findings obtained from the clinical use of vildagliptin and its effects on the liver. Material and Method: The study was conducted on 243 patients who were followed-up in our clinic between September 2016 and May 2018. The data were obtained by reviewing the patient files retrospectively. Result: A decrease was detected in the aminotransferases after the treatment with vildagliptin, which was statistically significant (ALT: decreased from 78 +/- 17 to 48 +/- 14 IU/L (p = 0.029), AST: decreased from 63 +/- 13 to 41 +/- 11 IU/L (p=0.035); GGT: 20.5 +/- 3.2 and 19.1 +/- 6.3 (p=0.682)). Vildagliptin reduces the insulin resistance and Body Mass Index in patients. Discussion: It was determined that Vildagliptin is a safe treatment option for Type 2 Diabetes management.en10.4328/ACAM.5983info:eu-repo/semantics/openAccessType 2 DiabetesVildagliptinSafetyLiver FunctionsArticle105529531N/A